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Abstract
The pathogenesis of gallbladder cancer presenting synchronously with malignancy of the bile duct has not been clearly
understood. The possible causes for the simultaneous presence of these tumors could be due to local spread, metastases, de
novo multifocal origin, or as part of a field change in the extrahepatic biliary apparatus. In this article, we discuss the cases of
four patients with simultaneous gallbladder and bile duct malignancies and analyze their individual pathologies to provide
an explanation into the mechanisms that may play a role in such conditions.
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Introduction
Synchronous malignancies within the extrahepatic
biliary tree are a rare cause for and there may be the
simultaneous presence of gallbladder cancer coexist-
ing with bile duct cholangiocarcinoma. The possible
explanations for such an occurrence could range from
the rare synchronous malignancies to local spread, to
metastasis.
The majority of cases of synchronous malignancies
reported are from Japan [14], where malignancies
are usually associated with anomalous pancreatic bile
duct junction (APBDJ). This association with APBDJ
is not an absolute necessity, as shown by Kurosaki et
al. [5] in a series of seven patients. An often confused
clinical scenario has been that of local metastasis from
a primary in the biliary tree leading to the misdiag-
nosis of synchronous malignancy. Warren et al. [6]
and Gertsch et al. [7] have attempted to describe
criteria for differentiation of the two conditions.
Over the past few decades, the reasons for labeling
extrahepatic biliary cancers as synchronous have been
based on multifocal origin [8]. The criteria for
differentiating between synchronous primaries and
metastasis are still being developed [9]. Gallbladder
cancer, in patients without APBDJ, does not follow
the adenoma-carcinoma but rather the dysplasia in
situ invasive carcinoma sequence [10,11].
The field cancerization theory was first introduced
in 1953 by Slaughter when describing the concept in
the aerodigestive tract [12]. This concept has been
used to explain the possibility of distant related
primary tumors in the upper aerodigestive tract [13].
The p53 gene mutations have been closely asso-
ciated with determination of clonality [13]. Allelic loss
or deletions at the TP53 locus (17p13) have been
reported ranging from 58% to 92% in gallbladder
cancer [14,15]. These deletions have been noted at
histologically normally appearing epithelium near
gallbladder cancer [14].
In discussing the cases of four random patients with
simultaneous gallbladder and bile duct malignancies
who presented to us, our aim was to describe the
various pathological possibilities in which gallbladder
cancer may occur synchronously with a malignancy of
the extra-hepatic bile duct.
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Case reports
Case 1
A 49-year-old male referred to us with obstructive
jaundice and pruritis that had developed over 2
months. He had undergone endoscopic retrograde
cholangiopancreatography (ERCP) with papillotomy
and stenting with a 10Fr plastic stent in view of a
stricture of the lower common bile duct (CBD). On
examination, the patient was icteric and generally well
preserved. His blood examination revealed direct
hyperbilirubinemia (serum bilirubin2.80 mg/dl)
with a CA19-9 level of 0 units/ml. A targeted
endoscopic ultrasound (EUS) was performed which
showed a hypoechoic tumor in the lower CBD
extending to the pancreas (uT4N0) (Figure 1a). A
contrast-enhanced computed tomography (CT) scan
of the abdomen (Figure 1b) showed a mild thickening
of the fundus of the gall bladder with altered
attenuation extending into segment IVB of the liver.
There was intrahepatic biliary dilatation with evidence
of CBD stent in situ. The patient was taken for
surgery, where the findings were a neoplastic mass in
the fundus of the gall bladder infiltrating the liver with
pericholedochal lymphadenopathy. There was an-
other separate neoplastic mass in the lower CBD.
An extended cholecystectomy with extrahepatic CBD
excision with a pancreaticoduodenectomy with radical
lymphadenectomy was performed (Figure 1c, d).
Intra-operative ultrasonography was done to rule out
other lesions in the pancreas as well as metastasis in
the liver. A frozen section confirmed the negative
proximal margin of the CBD. Postoperative histo-
pathology revealed a poorly differentiated adenocar-
cinoma of the gallbladder (T3N1) along with a poorly
differentiated adenocarcinoma of the lower CBD
(T3N1) with no anatomical continuity between the
two tumors with a solitary lymph node metastasis.
The patient is disease-free at 5 months’ follow-up.
Case 2
A 49-year-old male presented to us with obstructive
jaundice and pruritis that had developed over 1
month. On examination, the patient was icteric
with a palpable gall bladder. His blood examination
revealed direct hyperbilirubinemia (serum bilirubin
27.19 mg/dl) with a CA19-9 level of 117322 units/ml.
ERCP revealed a stricture extending from the prox-
imal to the mid-CBD. In view of the suboptimal
general condition of the patient with respect to
surgical risk, the decision was taken to perform an
ERCP with stenting with the relief of jaundice prior to
surgery. Papillotomy was performed and a 10Fr
plastic stent was placed. The patient developed post-
ERCP pancreatitis, which was mild and settled with
conservative management. Once the episode of acute
pancreatitis subsided, a contrast-enhanced CT scan of
the abdomen (post-ERCP) was performed which
showed a distended gallbladder with dilatation of the
intrahepatic biliary radicles in both lobes of the liver.
The patient underwent surgical exploration, which
revealed a neoplastic mass in the neck of the gall
bladder contiguous with the hilar cholangiocarci-
noma. An extended extrahepatic bile duct excision
with cholecystectomy was performed. However, the
entire biliary tree down to the intrapancreatic portion
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Figure 1. Images of Case 1. (a) Endoscopic ultrasonography image
showing tumor in the lower CBD with a stent in situ. (b) Intra-
operative photograph showing the excised gallbladder with wedge of
liver, pancreas divided at the neck and the exposed portal vein
following CBD resection. (c) Photograph showing resected speci-
mens of radical cholecystectomy and pancreaticoduodenectomy
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of the CBD, distally, and the right and left hepatic
ducts (proximally), revealed dysplasia on frozen sec-
tion (field cancerization). A hepaticojejunostomy was
performed and the patient was pencilled in for post-
operative intrabiliary radiotherapy. Postoperative his-
topathology revealed a moderately differentiated
adenocarcinoma of the neck of the gallbladder, cystic
duct, common hepatic duct (CHD), and CBD.
Lymphovascular emboli and perineural invasion
were seen. Both the proximal and distal cut margins
showed evidence of tumor. The patient is disease-free
at a follow-up of 6 months.
Case 3
A 56-year-old male presented to us with obstructive
jaundice and pruritis that had developed over 1
month. On examination, he was jaundiced with a
palpable lump in the right hypochondrium. His blood
examination revealed direct hyperbilirubinemia
(serum bilirubin16.30 mg/dl) with a CA19-9 level
of 38.75 units/ml. A contrast-enhanced CT of the
abdomen showed a short segment tight stricture in
the proximal CBD, just beyond the confluence,
suggestive of a cholangiocarcinoma. Preoperative
Doppler ultrasound showed involvement of the ante-
rior branch of the right hepatic artery with no
involvement of the portal vein. In view of the good
general condition of the patient with a normal
coagulation profile, it was decided to subject him to
surgery without preoperative stent placement. At
surgery, he was found to have a neoplastic mass in
the mid-CBD involving the anterior branch of the
right hepatic artery. A radical extrahepatic bile duct
excision with cholecystectomy was performed. On
frozen section, both the margins of resection were free
of tumor. A roux-en-y hepaticojejunostomy was
performed. Postoperative histopathology revealed a
moderately differentiated adenocarcinoma of the
CBD (full thickness and extending to the periductal
fat) involving the CHD and CD. Lymph nodes
dissected did not show evidence of tumor. Both the
proximal and distal cut margins showed no evidence
of tumor. The patient is disease-free at 5 months’
follow-up.
Case 4
A 48-year-old male presented to us with obstructive
jaundice 15 days. On examination, the patient had a
palpable lump in the right hypochondrium. His blood
examination revealed normal bilirubin levels (serum
bilirubin1.01 mg/dl) with a CA19-9 level of 2105
units/ml. A contrast-enhanced CT of the abdomen
showed an irregular thickening of the wall of the
gallbladder with soft tissue density in the fundus. An
MRCP revealed a stricture of the CHD just distal to
the confluence as well as in the distal CBD. Diag-
nosed as a case of locally advanced gallbladder cancer,
the patient was given four cycles of anterior che-
motherapy (Gemcitabine and Cisplatinum). The
MRCP that was performed after the chemotherapy
showed disease regression (Figure 2a). PET CT
imaging failed to show active disease. The patient
was therefore considered for surgical resection. At
surgery, he was found to have a neoplastic mass in the
gall bladder involving the CBD with a solitary
metastasis in segment 3 of the liver. A radical
cholecystectomy with radical extrahepatic bile duct
excision was performed. In view of no further lesions
detectable on intra-operative ultrasonography, a left
lateral segmentectomy was also performed (Figure
2b). A 2-duct hepaticojejunostomy had to be done
owing to the right posterior sectoral duct having an
anomalously low insertion in the CHD. On frozen
section, all margins of the resection were free of
tumor. Postoperative histopathology revealed a mod-
erately differentiated adenocarcinoma involving the
neck of the gall bladder and the CHD. Lymph nodes
dissected did not show evidence of tumor. All the
surgical margins were clear. The patient is disease-free
at 5 months’ follow-up.
Discussion
When we analyse these four clinical scenarios, we can
appreciate that possibly there are different patterns of
Figure 2. Image of the four modes of spread (GBgall bladder,
CDcytic duct, CBDcommon bile duct, LHDleft hepatic
duct, RPright posterior sectoral duct, RAright anterior sectoral
duct).
50 P. J. Shukla et al.
disease spread. In the first patient, the lack of
anatomical continuity between the two tumors seems
to favor the likelihood of a truly synchronous malig-
nancy. Synchronous gallbladder and CBD malignan-
cies are rare [5]; however, there are increasing reports
suggesting that they are more common than earlier
reported, probably due to inadequate sampling of the
gall bladder when performing a resection for extra-
hepatic bile duct malignancies. Their occurrence is
seen to be approximately 57.4% [5,16,17] in Japan,
where APBDJ is an important etiology [14]. This
clinical entity is often confused with metastasis from a
primary elsewhere in the biliary tree. Gertsch et al. [6]
have suggested that the best way to differentiate these
two entities is by applying the following criteria, viz.:
1) No direct continuity between the two tumors, 2) a
growth pattern typical of a primary tumor, 3) and
clear histologic differences between the two tumors.
These criteria, however, may not be sufficient to
confirm synchronicity, especially in malignancies of
the extrahepatic biliary tree. Kurosaki et al. [5] have in
fact advised the mapping technique to confirm the
distinctness of the two lesions.
Over the past few decades, the reasons for labeling
extrahepatic biliary cancers as synchronous have been
based on multifocal origin [8]. The criteria for
differentiating between synchronous primaries and
metastasis are still being developed [9]. Gallbladder
cancer, in patients without APBDJ, does not follow
the adenoma-carcinoma but rather the dysplasia in
situ invasive carcinoma sequence [10,11]. Intra-
epithelial spread may also contribute to multifocality
[9]. It is important to note, though, that this has been
demonstrated to occur in only 4% of persons with
papillary adenocarcinomas [18].
The second case seems best explained on the
concept of field cancerization. The field cancerization
theory was first introduced in 1953 by Slaughter when
describing this concept in the aerodigestive tract [12].
The field cancerization theory has been used to
explain the possibility of distant related primary
tumors in the upper aerodigestive tract [13]. Unfor-
tunately, the theory of field cancerization is seldom
referred to in the case of malignancies of the extra-
hepatic biliary tree.
The biliary tree is almost exclusively exposed to
concentrated bile, bile salts, and bile acids. Hence,
there has to be an effect of the bile on the lining
epithelium of the biliary tree and, consequently, on
carcinogenesis [19]. This has been noted in patients
with APBDJ. Findings that further strengthen the
opinion of bile chemistry and the idea of field
cancerization have been the detection of high levels
of secondary bile acids (with accompanying raised
biliary deoxycholates) [20] and heavy metals as
contaminants (metallothionein) [21] in the bile of
patients with gallbladder cancer. While it may be
argued that these findings, especially the former,
have not stood the test of time, there are factors in
the bile that need to be studied further if we are to
understand the pathogenesis of gallbladder and biliary
cancer.
In the case of field cancerization, the phenotype is a
result of a molecular event affecting multiple cells
separately and independently of each other, or a single
molecular event in a single clonal progenitor that
leads to widespread clonal expansion or an alternative
means of undergoing lateral spread across the mucosa
[13].
The p53 gene mutations have been closely asso-
ciated with determination of clonality [13]. Allelic loss
or deletions at the TP53 locus (17p13) reported
ranging from 58% to 92% in gallbladder cancer
[14,15] have been noted at histologically normally
appearing epithelium near gallbladder cancer [14].
Hori et al. [9] concluded that more studies on p53
mutations are needed in synchronous malignancies
unrelated to APBDJ.
Since gallbladder cancers occur more frequently in
females [22], X-chromosome inactivation studies
could be used to determine clonal similarity between
such synchronous tumors.
The role of epigenetics in field cancerization has
been shown in the stomach [23,24], liver [25], colon
[2628], Barrett’s esophagus [29], lungs [30], breasts
[31], and kidneys [32]. Studies on DNA methylation
in gallbladder cancer have been performed by House
et al. [33]. While studying chromosome 3p, Riquelme
et al. [34], too, have demonstrated a very high
frequency of GBC methylation in SEMA3B (92%)
and FHIT (66%). The time thus seems opportune to
explore the role of epigenetics in field cancerization of
gallbladder cancer.
Loss of heterozygosity is observed in at least 21
chromosomal regions in gallbladder cancer [35].
Chang et al. [15] have shown that LOH on 5q21
Figure 3. MRCP picture showing stricture of the CHD just distal
to the confluence as well as in the distal CBD with a lesion in the
gall bladder.
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(APC-MCC genes; 666%) is an early event change,
while LOH at 3p (2052%) and 9p are related to
progression in gallbladder cancer. They also showed
that LOH on 13q (Rb gene, 2030%) and 18q (DCC
gene, 1831%) is likely to be a late event and that
LOH on 17p occurs in dysplasia but also increases
during subsequent stages [36].
The third and fourth cases are representative of
cancers spreading to adjacent tissues by local exten-
sion. The possible routes may be [11,18]: 1) Peri-
ductal connective tissue (Case 3), 2) perineural, and
3) lymphatics.
Involvement of the cystic duct and neck of the
gallbladder by tumors of the mid-CBD has been well
documented [11]. Similarly, tumors of the gallbladder
have been shown to involve the bile duct. The possible
manner of cancer spread in these four tumors is
shown in Figure 3. The management algorithm for
such lesions needs to be thought through carefully,
keeping in mind that the aim is to achieve a complete
microscopic resection for improved outcomes in these
patients [37]. In circumstances where the synchro-
nous disease has not yet metastasized to distant
organs, as in case 1, and if radical simultaneous
resection is feasible, it should be attempted. On the
other hand, in the unfortunate situation where there is
field cancerization, the options are limited. It is
usually not possible to obtain complete removal of
the cancer and therefore there is a limit to the
advantages of radical resection.
Prognosis in such conditions depends on whether
the simultaneous lesion is a metastasis or a synchro-
nous one. Metastatic disease [38], perineural invasion
[39], and involvement of cystic duct [40] have been
shown to be associated with poor prognosis, whereas
in the case of synchronous lesions a fairly good
prognosis has been reported if a complete surgical
resection of the disease is possible [5].
Taking into consideration the limitations of the
present-day options of adjuvant therapy, it is essential
that complete removal of the tumor should be the goal
in patients capable of withstanding a major resection.
References
[1] Nakao A, Sakagami K, Uda M, Mitsuoka S. Double cancers of
the gallbladder and bile duct with anomalous choledochopan-
creatic duct junction. J Gastroenterol 1997;/32:/1103.
[2] Takayashiki T, Miyazaki M, Kato A, Ito H, Nakagawa K,
Ambiru S, et al. Double cancer of gallbladder and bile duct
associated with anomalous junction of the pancreaticobiliary
ductal system. Hepatogastroenterology 2002;/49:/10912.
[3] Ueda N, Nagakawa T, Ohta T, Kayahara M, Ueno K, Konishi
I, et al. Synchronous cancer of the biliary tract and pancreas
associated with anomalous arrangement of the pancreatico-
biliary ductal system. J Clin Gastroenterol 1992;/15:/13641.
[4] Suzuki S, Nakamura S, Ochiai H, Baba S, Sakaguchi T,
Tsuchiya Y, et al. Double cancer of the gallbladder and
common bile duct associated with an anomalous pancreatico-
biliary ductal associated with a choledochal cyst: report of a
case. Surg Today 1999;/29:/6515.
[5] Kurosaki I, Watanabe H, Tsukada K, Hatekayama K. Syn-
chronous primary tumors of the extrahepatic bile duct and
gallbladder. J Surg Oncol 1997;/65:/25862.
[6] Warren S, Gates O. Multiple primary malignant tumors: a
survey of the literature and a statistical study. Am J Cancer
1981;/16:/1358414.
[7] Gertsch P, Thomas P, Baer H, Lerut J, Zimmermann A,
Blumgart LH. Multiple tumors of the biliary tract. Am J Surg
1990;/159:/3868.
[8] Helpap B. Malignant papillomatosis of the intrahepatic bile
ducts. Acta HepatoGastroenterol 1977;/24:/41925.
[9] Hori H, Ajiki T, Fujita T, Okazaki T, Suzuki Y, Kuroda Y, et
al. Double cancer of gall bladder and bile duct not associated
with anomalous junction of the pancreatobiliary duct system.
Jpn J Clin Oncol 2006;/36:/63842.
[10] Wistuba II, Miguel JF, Gazdar AF, Albores-Saavedra J.
Gallbladder adenomas have molecular abnormalities different
from those present in gallbladder carcinomas. Hum Pathol
1999;/30:/215.
[11] Albores-Saavedra J, Henson DE. Tumours of gallbladder and
extrahepatic bile ducts. Fascicle 23, 3rd edn. Armed Forces
Institute of Pathology, Washington, DC, 2000.
[12] Slaughter D, Southwick H, Smejkal W. ‘‘Field Cancerization’’
in oral stratified squamous epithelium: clinical implications of
multicentric origin. Cancer 1953;/6:/9368.
[13] Ha PK, Califano JA. The molecular biology of mucosal field
cancerization of the head and neck. Crit Rev Oral Biol Med
2003;/14:/3639.
[14] Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa
I, et al. Allele-specific mutations involved in the pathogenesis
of endemic gallbladder carcinoma in Chile. Cancer Res 1995;/
55:/25115.
[15] Chang HJ, Kim SW, Kim YT, Kim WH. Loss of hetero-
zygosity in dysplasia and carcinoma of the gallbladder. Mod
Pathol 1999;/12:/7639.
[16] Kozuka S, Tsubone M, Hachisuka K. Evolution of carcinoma
in the extrahepatic bile duct. Cancer 1984;/54:/6572.
[17] Chiijiwa K. Synchronous carcinoma of the gallbladder in
patients with bile duct carcinoma. ANZ J Surg. 1993;/63:/690
2.
[18] Fahim RB, McDonald JR, Richards JC, Ferris DO. Carci-
noma of the gallbladder: a study of its modes of spread. Ann
Surg 1962;/156:/11424.
[19] Strom BL, Soloway RD, Rios-Dalenz JL, Rodriguez-Martinez
HA, West SL, Kinman JL, et al. Biochemical epidemiology of
gallbladder cancer. Hepatology 1996;/23:/140211.
[20] Shukla VK, Tiwari SC, Roy SK. Biliary bile acids in
cholelithiasis and carcinoma of the gallbladder. Eur J Cancer
Prev 1993;/2:/15560.
[21] Shukla VK, Prakash A, Tripathi BD, Reddy DC, Singh S.
Biliary heavy metal concentrations in carcinoma of the
gallbladder: a case control study. Br Med J 1998;/317:/12889.
[22] Tada M, Yokosuka O, Omata M, Ohto M, Isono K. Analysis
of ras gene mutations in biliary and pancreatic tumors by
polymerase chain reaction and direct sequencing. Cancer
1990;/66:/9305.
[23] Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K,
Iguchi M, et al. High levels of aberrant DNA methylation in
Helicobacter pylori-infected gastric mucosae and its possible
association with gastric cancer risk. Clin Cancer Res 2006;/12:/
9889995.
[24] Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S,
Umemura S, et al. Higher methylation levels in gastric
mucosae significantly correlate with higher risk of gastric
cancers. Cancer Epidemiol Biomarkers Prev 2006;/15:/2317
21.
[25] Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R,
Hirohashi S. Genetic instability and aberrant DNA methyla-
tion in chronic hepatitis and cirrhosis  a comprehensive study
of loss of heterozygosity and microsatellite instability at 39 loci
52 P. J. Shukla et al.
and DNA hypermethylation on 8CpG islands in microdis-
sected specimens from patients with hepatocellular carcinoma.
Hepatology 2000;/32:/9709.
[26] Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M,
Porschen R. Hypermethylation of the p16INK4a promoter in
colectomy specimens of patients with long-standing and
extensive ulcerative colitis. Cancer Res 1998;/58:/39425.
[27] Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA.
Accelerated age-related CpG island methylation in ulcerative
colitis. Cancer Res 2001;/61:/35737.
[28] Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS,
Vilaythong J, et al. MGMT promoter methylation and field
defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;/
97:/13308.
[29] Eads CA, Lord RV, Kurumboor SK, Wickremasinghe K,
Skinner ML, Long TI, et al. Fields of aberrant CpG island
hypermethylation in Barrett’s esophagus and associated ade-
nocarcinoma. Cancer Res 2000;/60:/50216.
[30] Guo M, House MG, Hooker C, Qi Y, Brock MV, Herman JG.
Promoter hypermethylation of resected bronchial margins: a
field defect of changes? Clin Cancer Res 2004;/10:/51316.
[31] Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz
NM, et al. Mapping geographic zones of cancer risk with
epigenetic biomarkers in normal breast tissue. Clin Cancer
Res 2006;/12:/662636.
[32] Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi
S. Regional DNA hypermethylation and DNA methyltransfer-
ase (DNMT) 1 protein overexpression in both renal tumours
and corresponding nontumourous renal tissues. Int J Cancer
2006;/119:/28896.
[33] House MG, Wistuba II, Argani P, Guo M, Schulick RD,
Hruban RH, et al. Progression of gene hypermethylation in
gallstone disease leading to gallbladder cancer. Ann Surg
Oncol 2003;/10:/8829.
[34] Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II,
et al. Frequent epigenetic inactivation of chromosome 3p
candidate tumor suppressor genes in gallbladder carcinoma.
Cancer Lett 2007;/250:/1006.
[35] Saetta A, Gigelou F, Panastasiou PI, Koilakou SV, Kalekou-
Greca H, Miliaras D, et al. High-level microsatellite instability
is not involved in gallbladder carcinogenesis. Exp Mol Pathol
2006;/80:/6771.
[36] Hidaka E, Yanasigawa A, Sakai Y, Seki M, Kitagawa T,
Setguchi T, et al. Losses of heterozygosity on chromosomes
17p and 9p/18q may play important roles in early and
advanced phases of gallbladder carcinogenesis. J Cancer Res
Clin Oncol 1999;/125:/43943.
[37] Kondo S, Nimura Y, Kamiya J, Nagino M, Kanai M, Uesaka
K, et al. Mode of tumor spread and surgical strategy in
gallbladder carcinoma. Langenbecks Arch Surg 2002;/387:/
2228.
[38] Shirai Y, Ohtani T, Tsukada K, Hatakeyama K. Combined
pancreaticoduodenectomy and hepatectomy for patients with
locally advanced gallbladder carcinoma. Long Term results.
Cancer 1997;/80:/19049.
[39] Yamaguchi R, Nagino M, Oda K, Kamiya J, Uesaka K,
Nimura Y. Perineural invasion has a negative impact on
survival of patients with gallbladder carcinoma. Br J Surg
2002;/89:/11306.
[40] Nakata T, Kobayashi A, Miwa S, Soeda J, Miyagawa S.
Impact of tumor spread to the cystic duct on the prognosis of
patients with gallbladder carcinoma. World J Surg 2007;/31:/
15562.
Simultaneous gallbladder and lower bile duct malignancies 53
